definition for: #tymeSM88

TYME's lead candidate, oral SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancers

TYME Cancer Metabolism-Based Therapies (CMBTs™), SM-88, is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, both solid and liquid tumors, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious Grade 3 or higher adverse events. More information may be found on the TYME Technologies Inc. website.